NCT05189535View on ClinicalTrials.gov

"Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 3, 2021

Primary Completion Date

September 18, 2023

Study Completion Date

September 28, 2023

Conditions
Breast Cancer FemalePeripheral Neuropathy
Interventions
DRUG

Pentoxifylline

Pentoxifylline 400 mg oral tablet twice daily for 12 weeks.

DRUG

Paclitaxel

Paclitaxel I.V 80 mg/m2 weekly

DRUG

Placebo

placebo

Trial Locations (1)

11566

Ain Shams University hospitals, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT05189535 - "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients" | Biotech Hunter | Biotech Hunter